Small Cell Neuroendocrine Carcinoma of the Breast in a Case Report
This case report details the clinical course of a 56-year-old woman with rare, triple-negative primary small cell neuroendocrine carcinoma of the breast who, despite progressing through multiple lines of therapy including chemotherapy and targeted agents, was enrolled in a clinical trial for a DLL3 antibody-drug conjugate, highlighting the evolving landscape of biomarker-driven treatments for this aggressive subtype.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.